Quantcast
Last updated on April 18, 2014 at 10:36 EDT

Latest tumor Stories

2013-06-03 23:14:58

Scion Medical announces the introduction of Cassi Beacon, a breast biopsy tissue marker which provides excellent and permanent visualization ultrasound and other major imaging modalities. Newton, MA (PRWEB) June 03, 2013 Scion Medical Technologies, LLC announces the introduction of the Cassi Beacon tissue marker, the company´s newest addition to the Cassi breast biopsy product portfolio. The Cassi Beacon tissue marker is a single use marker which is placed into soft tissue during...

How And Where Breast Tumor Cells Become Dormant And What Causes Them To Become Metastatic
2013-06-03 19:49:37

Lawrence Berkeley National Laboratory The long-standing mystery behind dormant disseminated breast tumor cells and what activates them after years and even decades of latency may have been solved. Researchers with the U.S. Department of Energy (DOE)´s Lawrence Berkeley National Laboratory (Berkeley Lab) have identified the microenvironment surrounding microvasculature — the small blood vessels that transport blood within tissues — as a niche where dormant cancer cells...

2013-06-03 12:37:18

The combination of the immunotherapy drug ipilimumab and the investigational antibody drug nivolumab led to long-lasting tumor shrinkage in more than half of patients with metastatic melanoma, according to results from a Phase I trial simultaneously published online on Sunday, June 2, in The New England Journal of Medicine and presented by Memorial Sloan-Kettering Cancer Center researchers at the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO). Several patients...

2013-06-03 12:32:40

The HER2 growth-factor gene is known to be over-active in breast and gastro-esophageal cancers. But now, irregularities in the genes 's expression – among them mutations, amplifications, substitutions, and translocations – have been found in 14 different advanced solid tumors. The results of the study of more than 2,000 tumors, being presented at the annual meeting of the American Society of Clinical Oncology (ASCO), both surprised researchers and provided hope that some of...

2013-06-03 10:48:37

Results of a randomized phase III clinical trial conducted by the Radiation Therapy Oncology Group (RTOG) determined that adding bevacizumab to initial treatment for glioblastoma (GBM) did not improve patient overall survival or progression-free survival. Results were reported June 2 during the plenary session of the American Society of Clinical Oncology 2013 Annual Meeting. GBM is the most common primary malignant brain tumor in adults and, despite treatment advances in recent years, the...

2013-06-03 08:28:12

Activity with VAL-083 Observed in Recurrent Malignant Glioma and Progressive Secondary Brain Tumors VANCOUVER, British Columbia and MENLO PARK, Calif., June 3, 2013 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar") announced that the company presented a poster entitled "Phase I/II Study of VAL-083 (dianhydrogalactitol) in Patients with Recurrent Malignant Glioma or Progressive Secondary Brain Tumor" at the American Society of Clinical Oncology (ASCO) Annual...

2013-06-03 08:27:09

Test Validated by Largest Melanoma Biomarker Program of its Kind Data Being Presented at American Society of Clinical Oncology Annual Meeting FRIENDSWOOD, Texas, June 3, 2013 /PRNewswire/ -- Castle Biosciences Inc. announced that data from studies of its DecisionDx-Melanoma test are being presented today at the 49(th) Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago (Abstract #9022). Results show that the gene expression profile test strongly predicts...

2013-06-02 08:20:14

Analysis of world's largest commercial cancer patient database uncovers clinically actionable targets IRVING, Texas, June 2, 2013 /PRNewswire/ -- Caris Life Sciences(TM), a leading biosciences company focused on fulfilling the promise of personalized medicine, will present findings today at the 2013 ASCO annual meeting from the analysis of its Caris Molecular Intelligence(TM) database. This database examined the results of molecular profiling of both common and rare cancer types for...

2013-06-01 16:20:12

CHICAGO and SAN FRANCISCO, June 1, 2013 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) announced today that it presented a series of target-specific biomarkers that are being evaluated in the development of etirinotecan pegol for the treatment of breast cancer. Etirinotecan pegol is a unique, next generation, targeted topoisomerase I inhibitor currently in Phase 3 clinical development as a potential treatment for patients with locally recurrent or metastatic breast cancer. The BEACON...

2013-05-31 08:25:09

PORTSMOUTH, N.H., May 31, 2013 /PRNewswire/ -- Novocure, a commercial stage private oncology company, announced today that data from pre-clinical and clinical studies evaluating NovoTTF(TM) Therapy will be presented and published online as part of the 49th Annual Meeting of the American Society for Clinical Oncology (ASCO) in Chicago, IL, May 31-June 4, 2013. The clinical data includes a detailed analysis of time to tumor progression for patients with recurrent glioblastoma treated with...